Merck's Companion in the Fight Against Alzheimer's

A cure for Alzheimer's disease is one of the most sought-after prizes in the pharmaceutical industry today. The tragic degenerative effects of this illness are widely known, but drugmakers have been unable to find medicines that can effectively slow its progression. The development of a drug shared by Pfizer, Johnson & Johnson, and Elan was stopped last summer, and Eli Lilly's phase 3 compound solanezumab displayed mixed results after the data was analyzed last autumn. Pharma titan Merck  (NYSE: MRK  ) is also in the race to find an effective treatment with its experimental Alzheimer's drug, called MK-8931, and the company is currently enrolling patients in its phase 2/3 study.

Today, in an effort to enroll the appropriate subgroup of patients in its study, Merck announced that it has an agreement in place with Luminex (NASDAQ: LMNX  ) for a companion diagnostic that can help diagnose Alzheimer's disease. Health-care Max Macaluso analyst discusses the importance of this deal in the following video.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more, click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2311427, ~/Articles/ArticleHandler.aspx, 12/18/2014 1:29:11 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement